AbbVie Inc. (ABBV) Income statement
Top 20 of 28 line items reported by ABBV · 250+ in the full API →
AbbVie Inc. (ABBV) · Income Statement
Consolidated Statements of Operations
Annual · In millions USD, except per-share data · Latest filed Feb 20, 2026 · FY ends Dec 31
| Fiscal Years Ended | |||||
|---|---|---|---|---|---|
FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | Trend | |
| Total Revenue | $61,160 | $56,334 | $54,318 | $58,054 | |
| Cost of Revenue | 18,204 | 16,904 | 20,415 | 17,414 | |
| Gross Profit | $42,956 | $39,430 | $33,903 | $40,640 | |
| Other Operating Expenses | 27,881 | 30,293 | 21,146 | 22,523 | |
| Total Operating Expenses | 46,085 | 47,197 | 41,561 | 39,937 | |
| Operating Income | $15,075 | $9,137 | $12,757 | $18,117 | |
| EBIT (Earnings Before Interest & Tax) | 15,075 | 9,137 | 12,757 | 18,117 | |
| Add: Depreciation & Amortization | 8,139 | 8,386 | 8,698 | 8,467 | |
| EBITDA (Non-GAAP) | $23,214 | $17,523 | $21,455 | $26,584 | |
| Interest Income | (2,627) | (2,160) | (1,684) | (2,044) | |
| Interest Expense | -2,893 | -2,808 | -2,224 | -2,230 | |
| Foreign Exchange Gain (Loss) | (58) | (21) | (146) | (148) | |
| Non-Operating Income (Expense) | $(5,578) | $(4,989) | $(4,054) | $(4,422) | |
| Income Before Taxes (EBT) | $6,597 | $3,716 | $6,250 | $13,477 | |
| Provision for Income Taxes | 2,364 | (570) | 1,377 | 1,632 | |
| Effective Tax Rate | 35.8% | (15.3%) | 22% | 12.1% | |
| Net Income | $4,226 | $4,278 | $4,863 | $11,836 | |
| Shares Outstanding | 1,769 | 1,769 | 1,768 | 1,771 | |
| Diluted Earnings Per Share | $2.36 | $2.39 | $2.72 | $6.63 | |
| Gross Margin | 70.2% | 70% | 62.4% | 70% | |
8 more line items available via the API
Research & DevelopmentSales, General & AdministrativeAsset Impairment ChargesDiluted Shares OutstandingBasic Earnings Per ShareOperating MarginOther OpEx MarginNet Margin
Ask your agent:
get_financialsAPIGET /api/v1/companies/ABBV/income-statement?period=annual&years=8Docs →